Clearnote Health
Jim has more than 20 years of experience directing the global commercialization of molecular diagnostics and cancer therapeutics in oncology at companies including Searle/Pfizer and Genomic Health/Exact Sciences. He was chief commercial officer and global market lead for Oncotype DX breast, colorectal and prostate cancer products. In his more than two decades in the industry, he has developed a breadth of expertise in sales, marketing, product development, medical affairs and reimbursement strategy. Working and living internationally, Vaughn launched both diagnostic and therapeutic oncology, hematology, and urology products. Jim earned his MBA from the Kellogg School of Business at Northwestern and holds a BS in Pharmacy from Creighton University.
This person is not in any teams
This person is not in any offices
Clearnote Health
ClearNote Health (formerly Bluestar Genomics) – Cancer detection company enabling people at risk for high-mortality cancers to live longer, healthier lives. They focus on developing non-invasive tests to detect cancer through a standard blood draw earlier than existing methods by harnessing the power of epigenomics. They apply their proprietary epigenomic platform, combining biology and artificial intelligence, to identify DNA-based changes in biology as cancer develops. With lead programs in non-invasive early detection of pancreatic and ovarian cancers in patients at the highest risk for these diseases. Headquartered in the U.S, the company’s CLIA and CAP-accredited laboratory is located in San Diego, Calif., with additional presence in the San Francisco Bay Area and internationally.